RT Journal Article
SR Electronic
T1 Acceptability and feasibility of digital adherence technologies for tuberculosis treatment supervision: A meta-analysis of implementation feedback
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.26.23284950
DO 10.1101/2023.01.26.23284950
A1 Guzman, Kevin
A1 Crowder, Rebecca
A1 Leddy, Anna
A1 Maraba, Noriah
A1 Jennings, Lauren
A1 Ahmed, Shahriar
A1 Sultana, Sonia
A1 Onjare, Baraka
A1 Shilugu, Lucas
A1 Alacapa, Jason
A1 Levy, Jens
A1 Katamba, Achilles
A1 Kityamuwesi, Alex
A1 Bogdanov, Aleksey
A1 Gamazina, Kateryna
A1 Cattamanchi, Adithya
A1 Khan, Amera
YR 2023
UL http://medrxiv.org/content/early/2023/01/28/2023.01.26.23284950.abstract
AB Introduction Digital adherence technologies (DATs) have emerged as an alternative to directly observed therapy (DOT) for supervisions of tuberculosis (TB) treatment. We conducted a meta-analysis of implementation feedback obtained from people with TB and health care workers (HCWs) involved in TB REACH Wave 6-funded DAT evaluation projects.Methods Projects administered standardized post-implementation surveys based on the Capability, Opportunity, Motivation, Behavior (COM-B) model to people with TB and their health care workers. The surveys included questions on demographics and technology use, Likert scale questions to assess capability, opportunity, and motivation to use DAT and open-ended feedback. We summarized demographic and technology use data descriptively, generated pooled estimates of responses to Likert scale questions within each COM-B category for people with TB and health care workers using random effects models, and performed qualitative analysis of open-ended feedback using a modified framework analysis approach.Results The analysis included surveys administered to 1290 people with TB and 90 HCWs across 6 TB REACH-funded projects. People with TB and HCWs had an overall positive impression of DATs with pooled estimates between 4·0 to 4·8 out of 5 across COM-B categories. However, 44% of people with TB reported taking TB medications without reporting dosing via DATs and 23% reported missing a dose of medication. Common reasons included problems with electricity, network coverage, and technical issues with the DAT platform. DATs were overall perceived to reduce visits to clinics, decrease cost, increase social support, and decrease workload of HCWs.Conclusion DATs were acceptable in a wide variety of settings. However, there were challenges related to the feasibility of using current DAT platforms. Implementation efforts should concentrate on ensuring access, anticipating, and addressing technical challenges, and minimizing additional cost to people with TB.Author Summary Digital adherence technologies (DATs) are increasingly being implemented as an alternative to traditional directly observed therapy (DOT) for TB treatment. However, to date there are limited data on their feasibility and acceptability among both persons on treatment and health care workers, resulting in only a conditional recommendation for their use in TB treatment by the World Health Organization in their 2017 Guidelines for treatment of drug-susceptible tuberculosis and patient care.Our study provides information on the feasibility and acceptability of implementing and using different DATs in a variety of settings and target populations for TB treatment adherence. The use of a similar survey across multiple sites helps provides a common understanding of facilitators and barriers on the use of DATs as global and national TB programs consider the expansion of the use of these tools. Our evidence demonstrates a high acceptability of DATs and supports further implementation of DATs as a component of TB treatment support. However, implementation efforts need to address issues concerning access to these tools, the technical challenges that are associated with the platforms, while minimizing additional burdens and costs to people with TB.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Stop TB Partnerships TB REACH initiative with funding from the Bill and Melinda Gates Foundation (BMGF), grant number OPP1139029 and from the Global Affairs Canada (GAC), grant number CA-3-D000920001. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This manuscript is a meta-analayses of data collected from several different projects. Each project received local ethical approval for their data that they submitted for inclusion in this paper.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscriptCOM-BCapability, Opportunity, Motivation, BehaviorBMGFBill and Melinda Gates FoundationDATDigital adherence technologyDR-TBDrug-resistant TBDS-TBDrug-sensitive TBGACGlobal Affairs CanadaHCWHealth care workersTBTuberculosisTDFTheoretical Domains FrameworkUTAUTUnified Theory of Acceptance and Use of TechnologyVDOTVideo directly observed therapyWHOWorld Health Organisation